Searchable abstracts of presentations at key conferences in endocrinology

ea0034p148 | Clinical practice/governance and case reports | SFEBES2014

Diabetes: the forgotten complication of parathyroidectomy

Othonos Nantia , Patel Vinod , Nair Rajiv , Ayre Stephen , Saravanan Ponnusamy

A 64-year-old female presented to the acute medical take with hypercalcaemia. She had a 3 weeks history of polyuria, polydipsia, constipation, intermittent abdominal pain and feeling depressed. She reported weight loss of 3.5 kg over the past 6 months. She denied symptoms of dysphagia, dyspnoea, haemoptysis, haematemesis, or malaena. Her past medical history included anaemia, ischaemic heart disease, chronic obstructive pulmonary disease and uterine prolapse. She was an ex-smo...

ea0050oc1.2 | Early Career Oral Communications | SFEBES2017

Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids

Marjot Tom , Othonos Nantia , Woods Conor , Hazlehurst Jonathan , Moolla Ahmad , Hodson Leanne , Tomlinson Jeremy

Glucocorticoids (GC) are commonly prescribed and their use is associated with adverse metabolic side effects. 5a-reductase (5aR) inhibitors are also frequently prescribed mainly for their ability to inhibit the conversion of testosterone to dihydrotestosterone. However, they also have a role to inactivate and clear GCs. We hypothesised that 5aR inhibitors have the potential to exacerbate the adverse metabolic effects of GCs. We conducted a prospective, randomised, study in 19 ...

ea0050oc1.2 | Early Career Oral Communications | SFEBES2017

Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids

Marjot Tom , Othonos Nantia , Woods Conor , Hazlehurst Jonathan , Moolla Ahmad , Hodson Leanne , Tomlinson Jeremy

Glucocorticoids (GC) are commonly prescribed and their use is associated with adverse metabolic side effects. 5a-reductase (5aR) inhibitors are also frequently prescribed mainly for their ability to inhibit the conversion of testosterone to dihydrotestosterone. However, they also have a role to inactivate and clear GCs. We hypothesised that 5aR inhibitors have the potential to exacerbate the adverse metabolic effects of GCs. We conducted a prospective, randomised, study in 19 ...

ea0049gp70 | Developmental & Protein Endocrinology | ECE2017

The adverse effects of prescribed glucocorticoids are worsened by co-administration of 5α-reductase inhibitors

Marjot Tom , Othonos Nantia , Woods Conor , Hazlehurst Jonathan , Moola Ahmad , Hodson Leanne , Tomlinson Jeremy

Introduction: Glucocorticoids (GC) are prescribed to 2–3% of the population of the UK and USA. Their use is associated with a significant side effect profile that includes the development of central obesity, insulin resistance and type 2 diabetes. 5α-reductase (5αR) inhibitors (Finasteride and Dutasteride) are also commonly prescribed in the context of prostate disease, where they inhibit the conversion of testosterone to dihydrotestosterone. Additionally, they ...

ea0099p219 | Adrenal and Cardiovascular Endocrinology | ECE2024

11β-hydroxysteroid dehydrogenase type 1 inhibition unmasks multiple pathways that may mitigate the adverse effects of prescribed prednisolone

Pofi Riccardo , Coll Sergi , Othonos Nantia , Miller Hamish , Potter Tom , Escott Jane , Whittaker Andrew , Monfort Nuria , Ventura Rosa , Tomlinson Jeremy

Background: Prednisolone is the most commonly prescribed exogenous glucocorticoid(GC) and its use is frequently associated with the development of iatrogenic Cushing’s Syndrome. Once administered, prednisolone is rapidly converted to inactive prednisone by renal 11β-hydroxysteroid dehydrogenase type 2(11β-HSD2) and subsequently reactivated by 11β-HSD1. We have shown previously that 11β-HSD1 inhibition(with the selective 11β-HSD1 inhibitor, AZD4017...

ea0070oc3.6 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

11β-Hydroxysteroid dehydrogenase type 1 inhibition protects against the development of adverse metabolic and bone effects of prednisolone: A randomized, double-blind, placebo-controlled trial

Othonos Nantia , Pofi Riccardo , Arvaniti Anastasia , Whittaker Andrew , Stewart Paul , Coleman Ruth , Agbaje Olorunsola , Milton Joanne , Holman Rury , Tomlinson Jeremy W

Glucocorticoids (GC) are commonly prescribed, but their use is associated with significant adverse metabolic and bone effects. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active GC within tissues, tightly controlling the availability of GC to bind and activate the GC receptor; Our preclinical data have shown that 11β-HSD1 knock out mice resist the adverse effects of exogenous GC excess. We have now conducted a randomized, double-blind, placebo...